普伐他汀治疗肝酶升高的急性冠脉综合征38例的安全性  

Safety of pravastatin in 38 acute coronary syndrome patients with elevated liver enzyme

作　　者：吕瑞娟[1] 张运[2] 陈玉国[1] 孙祎[1] 王文君[1] 

机构地区：[1]山东大学齐鲁医院急诊科,山东济南250012 [2]山东大学齐鲁医院心内科,山东济南250012

出　　处：《中国新药与临床杂志》2006年第8期595-597,共3页Chinese Journal of New Drugs and Clinical Remedies

摘　　要：目的：观察肝酶升高的急性冠脉综合征(ACS)病人应用普伐他汀的安全性。方法：ACS病人120例,根据入院时血清丙氨酸转氨酶(ALT)的情况分为肝酶升高组(ALT＞40 IU·L^(-1))38例和肝酶正常组(ALT≤40IU·L^(-1))82例。2组病人在入院时均接受抗血小板、抗凝、肾上腺素β受体阻滞药、血管紧张肽转换酶抑制药、硝酸酯等药物的同时给予普伐他汀20 mg,po,qd,分别于给药d10,d30后复查肝功能,比较用药前后ALT的变化,计算2组病人用药后肝损伤所占比率。结果：普伐他汀治疗10 d,30d后,肝酶升高组与肝酶正常组比较,肝损伤发生率无明显差异(5% vs 2%,P＞0．05和3% vs 2%,P＞0．05)。普伐他汀治疗1mo后肝酶升高组肝功能好转[(45±s 15)IU·L^(-1) vs (66±19)IU·L^(-1),P＜0．01]。结论：肝酶升高的急性冠脉综合征早期应用普伐他汀安全,不增加肝毒性。AIM： To investigate the safety of pravastatin in acute coronary syndrome （ACS） patients with elevated liver enzyme. METHODS： One hundred and twenty ACS patients were divided into elevated liver enzyme group （ALT 〉 40 IU·L^-1, 38 patients） and normal group （ALT ≤ 40 IU·L^-11, 82 patients） . All patients were administered with 20 mg pravastatin per day, the effects of pravastatin on liver biochemistries and tissue damage were assessed by detecting ALT levels 10 d and 30 d after the administrations. RESULTS： There were no significant differences in incidences of liver injury 10 d and 30 d after administration in the comparisons between two groups （5 % vs 2 %, P 〉 0.05; 3 % vs 2 %, P 〉 0.05） . Liver function in elevated liver enzyme group had been improved 30 d after administration with pravastatin （（45±s 15） IU·L^-1 vs （66± 19） IU·L^-1, P 〈 0.01） . CONCLUTION： Early adimistrating pravastatin in ACS patients with elevated baseline liver enzyme is safe and does not increase hepatotoxicity.

关 键 词：冠状动脉疾病 普伐他汀 丙氨酸转氨酶 安全 

分 类 号：R972.6[医药卫生—药品]